RecruitingPhase 1 / Phase 2NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Sponsor: Genmab
Phoenix, AZ · Tucson, AZ · Los Angeles, CA · +34 more sites
Phase 1/2 Breast Cancer clinical trials
36 recruiting Phase 1/2 breast cancer studies in the US. What trial phases mean
Other phases
RecruitingPhase 1 / Phase 2NCT07189871
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Sponsor: Radiopharm Theranostics, Ltd
Dothan, AL · Grand Rapids, MI · Omaha, NE · +2 more sites
RecruitingPhase 1 / Phase 2NCT07488676
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Sponsor: Astellas Pharma Global Development, Inc.
Birmingham, AL · Los Angeles, CA · Miami, FL · +15 more sites
RecruitingPhase 1 / Phase 2NCT05898399
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Sponsor: Artios Pharma Ltd
Grand Rapids, MI · New York, NY · Oklahoma City, OK · +4 more sites
RecruitingPhase 1 / Phase 2NCT05130801
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
Sponsor: Memorial Sloan Kettering Cancer Center
Montvale, NJ · New York, NY
RecruitingPhase 1 / Phase 2NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Sponsor: Gilead Sciences
New Haven, CT · Miami, FL · Boston, MA · +10 more sites
RecruitingPhase 1 / Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Sponsor: Bristol-Myers Squibb
Clovis, CA · Los Angeles, CA · Newport Beach, CA · +8 more sites
RecruitingPhase 1 / Phase 2NCT06330064
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Sponsor: Daiichi Sankyo
Los Angeles, CA · Whittier, CA · +15 more sites
RecruitingPhase 1 / Phase 2NCT05000294
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
Sponsor: University of Florida
Gainesville, FL
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Los Angeles, CA · San Francisco, CA · Aurora, CO · +25 more sites
RecruitingPhase 1 / Phase 2NCT07011654
Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Sponsor: M.D. Anderson Cancer Center
Houston, TX
RecruitingPhase 1 / Phase 2NCT07441889
HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)
Sponsor: University of Virginia
Charlottesville, VA
RecruitingPhase 1 / Phase 2NCT07198724
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Sponsor: Kristina A. Fanucci
Boston, MA
RecruitingPhase 1 / Phase 2NCT05608252
VS-6766+Abema+Fulv in Met HR+/HER- BC
Sponsor: Adrienne G. Waks
Boston, MA
RecruitingPhase 1 / Phase 2NCT05095207
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Sponsor: Icahn School of Medicine at Mount Sinai
New York, NY
RecruitingPhase 1 / Phase 2NCT05785741
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
Sacramento, CA · Santa Monica, CA · Coral Gables, FL · +12 more sites
RecruitingPhase 1 / Phase 2NCT06395519
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Sponsor: 858 Therapeutics, Inc.
Phoenix, AZ · New Haven, CT · Jacksonville, FL · +11 more sites
RecruitingPhase 1 / Phase 2NCT04333706
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Sponsor: University of Southern California
Los Angeles, CA · Gainesville, FL
RecruitingPhase 1 / Phase 2NCT06956690
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Sponsor: Hummingbird Bioscience
La Jolla, CA · Indianapolis, IN · Farmington Hills, MI · +2 more sites
RecruitingPhase 1 / Phase 2NCT05074290
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
Sponsor: University of Florida
Gainesville, FL
RecruitingPhase 1 / Phase 2NCT06926920
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Sponsor: Gilead Sciences
Los Angeles, CA · Atlanta, GA · Westwood, KS · +6 more sites
RecruitingPhase 1 / Phase 2NCT05490472
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Detroit, MI · St Louis, MO · Dallas, TX · +1 more sites
RecruitingPhase 1 / Phase 2NCT05256745
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Sponsor: Georgetown University
Washington D.C., DC · Hackensack, NJ
RecruitingPhase 1 / Phase 2NCT06943521
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Sponsor: Tanabe Pharma America, Inc.
Los Angeles, CA · Grand Rapids, MI · Columbus, OH · +1 more sites
RecruitingPhase 1 / Phase 2NCT06238921
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL
RecruitingPhase 1 / Phase 2NCT06249048
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Sponsor: Strand Therapeutics Inc.
Scottsdale, AZ · Beverly Hills, CA · Cleveland, OH · +3 more sites
RecruitingPhase 1 / Phase 2NCT06827613
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
Sponsor: Marengo Therapeutics, Inc.
Los Angeles, CA · Boston, MA · +3 more sites
RecruitingPhase 1 / Phase 2NCT06682793
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Sponsor: A2 Biotherapeutics Inc.
Gilbert, AZ · La Jolla, CA · Los Angeles, CA · +7 more sites
RecruitingPhase 1 / Phase 2NCT04503265
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
Sponsor: AtlasMedx, Incorporated
Los Angeles, CA · Baltimore, MD · Nashville, TN · +1 more sites
RecruitingPhase 1 / Phase 2NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Sponsor: GI Innovation, Inc.
Scottsdale, AZ · Jacksonville, FL · Rochester, MN · +2 more sites
RecruitingPhase 1 / Phase 2NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Sponsor: Simcha IL-18, Inc.
Scottsdale, AZ · Denver, CO · New Haven, CT · +3 more sites
Not yet recruitingPhase 1 / Phase 2NCT07743723
A Study of IOV-5001 in Adults With Advanced Solid Tumors
Sponsor: Iovance Biotherapeutics, Inc.
New York, NY
Not yet recruitingPhase 1 / Phase 2NCT07811232
A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers
Sponsor: Advenchen Pharmaceuticals, LLC.
Houston, TX
Not yet recruitingPhase 1 / Phase 2NCT07762703
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy
Sponsor: BreakBio Corp
Miami, FL
Not yet recruitingPhase 1 / Phase 2NCT07217990
Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer
Sponsor: Ohio State University Comprehensive Cancer Center
Columbus, OH
Not yet recruitingPhase 1 / Phase 2NCT07612254
aPBI Re-irradiation
Sponsor: Dartmouth-Hitchcock Medical Center
Lebanon, NH
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.